
ASO VISUAL ABSTRACT

ASO Visual Abstract: Time to Surgery and Thyroid Cancer Survival in the United States

Scott C. Fligor, MD^{1,2}, Betzamel Lopez, BS², Nishant Uppal, BS^{2,3}, Carrie C. Lubitz, MD, MPH, FACS^{2,4}, and Benjamin C. James, MD, MS, FACS^{1,2}

ded 103,812 adults with papillary thyroid cancer from 2004 to 2016 (https://doi.org/10.1245/s10434-021-09797-z). The median follow-up period was 55.2 months (interquartile range, 28.4–89.5 months). Increasing time to surgery was

associated with increased mortality. In the subgroup analysis, increasing delay was associated with worse overall survival for T1, T2, and T3 tumors, but not T4 tumors. Further research is necessary to assess the impact of surgical delay on disease-specific survival.



ACKNOWLEDGMENT This work was conducted with support from National Institutes of Health Award UL1 TR002541. Dr. Lubitz also is supported by the National Institutes of Health/National Cancer Institute Award R37 CA23195.

Dr. Scott C. Fligor and Ms. Betzamel Lopez should be considered cofirst authors.

DISCLOSURES There are no conflicts of interest.

© Society of Surgical Oncology 2021

B. C. James, MD, MS, FACS e-mail: bjames1@bidmc.harvard.edu

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

¹Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA; ²Harvard Medical School, Boston, MA; ³Harvard Business School, Boston, MA; ⁴Department of Surgery, Massachusetts General Hospital, Boston, MA

The first study to investigate time to surgery in papillary thyroid cancer using the National Cancer Database inclu-